. 2018 Dec 6;3:155. [Version 1] doi: 10.12688/wellcomeopenres.14909.1

Table 1. List of PfSPZ Challenge CHMI Studies in African Endemic Populations *.

Location	Study Type	Number of Volunteers	Route of Administration	Age (years)	Gender	Malaria Outcome ¹	Reference
Equatorial Guinea	Vaccine efficacy Vaccine efficacy	52 104	DVI DVI	18–35 18–45	Both Both	TBS ² TBS ²	NCT02859350 NCT03590340
Gabon	Infectivity Vaccine efficacy	20 12	DVI DVI	18–30 18–40	Both Both	TBS ² TBS ²	34 PACTR201503001038304
Gambia	Infectivity	30	DVI	18–35	Males	qPCR	NCT03496454
Kenya	Infectivity ³	28	IM	18–45	Both	TBS ²	31
Mali	Vaccine efficacy ⁴ Vaccine efficacy	62 45	DVI DVI	18–45 18–50	Both Both	TBS ² TBS ²	NCT02996695 NCT02627456
Tanzania	Infectivity ³ Vaccine efficacy Vaccine efficacy Vaccine efficacy	24 64 24 18 ^{^}	ID DVI DVI DVI	20–35 18–35 18–45 18–45	Males Males Both Both	TBS ⁵ TBS ² TBS ² TBS ²	30 35 NCT02613520 NCT03420053

*Current status as at 18 ^th September 2018. ¹Primary measure for malaria treatment/diagnosis; ²Studies included qPCR data for secondary parasitaemia analysis; ³Studies included dose optimisation for PfSPZ Challenge administration; ⁴PfSPZ Challenge in the context of chemoprophylaxis using chloroquine (PfSPZ-CVac); ⁵Studies included qRT-PCR data for secondary parasitaemia analysis; and ^PfSPZ Challenge including HIV positive individuals (N=9). DVI, direct venous inoculation; IM, intramuscular; ID, intradermal; qPCR, quantitative PCR; and TBS, thick blood smear.